Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 4 15Phase NA 10Phase 3 7Phase 1 6Phase 1/2 4Phase 2/3 2

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Breast Cancer Female 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20venetoclax 18Vincristine 18apatinib 17Trastuzumab 17Rituximab 17Prednisone 17Letrozole 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × pegylated granulocyte colony-stimulating factor × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2/3 Completed
586 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡